Novartis AG

NYSE:NVS

Drug Manufacturers - General

Healthcare
$155.21 -2.24%

-$3.38 today

Market cap
$293.13B
Beta
0.49
P/E (TTM)
20.7
EPS (TTM)
$7.06
Dividend yield
3.13%
52W Low $112.34High $170.46

Volume 2.75M

Average 1.56M

NVS Debt Repayment

Cash used to repay borrowings during the period.

Novartis AGNYSE: NVS

Debt Repayment · Q2 FY2026 · quarter ended Jun 2026

Debt repayment growth accelerates

Q2 FY2026 debt repayment of $2.15B rose 1089.8% year over year, ahead of the +704.5% change in trailing-twelve-month debt repayment. Sequentially, it fell 81.4% from the prior quarter.

Context

  • Debt repayment amounted to 5.0% of revenue in FY2025, down 3.5 pp from a year earlier.
  • Debt repayment increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +1089.8% holds above the trailing-twelve-month pace of +704.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$2.15B-81.4% QoQ
Last fiscal yearDec 2025
$2.72B-37.9% YoY
LTMJun 2026
$16.59B+704.5% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1089.8%——
1 year-37.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
2.72B USD
Year-over-year change
-37.9%

Debt Repayment vs competitors

How NVS compares with its peers on the latest reported figures

  • Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +704.5% is the 3rd highest of 10, against a peer median of +98.1%.
  • Debt repayment amounts to 29.8% of revenue for NVS, versus a peer median of 3.6%.
NVS Competitors
Debt Repayment for NVS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 36.44B DKK-8.0%—11.1%
MRKMerck & Co., Inc.LTM Jun 2026$18.64B USD+723.0%—28.1%
NVSNovartis AGLTM Jun 2026$16.59B USD+704.5%—29.8%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$6.49B USD+98.1%-0.9%13.2%
SNYSanofiLTM Jun 2026€3.21B EUR——6.6%
PFEPfizer Inc.LTM Jun 2026$1.78B USD+121.9%-72.4%2.8%
GILDGilead Sciences, Inc.LTM Jun 2026$1.29B USD-18.4%+6.0%4.2%
GSKGSK plcLTM Jun 2026£998.88M GBP+753.7%—3.0%
AZNAstraZeneca PLCLTM Sep 2026$793.27M USD+8.5%+11.3%1.3%
JNJJohnson & JohnsonLTM Sep 2026$787M USD-108.7%+8.9%0.8%
ABBVAbbVie Inc.LTM Jun 2026$418M USD+130.0%-70.3%0.6%
Peer median (excluding NVS) —+98.1%+2.6%3.6%

Competitors are the stored peer set for NVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income22.91B6.05B8.57B11.94B14.06B
Depreciation & Amortization5.6B6.71B8.28B6.07B5.35B
Deferred Income Tax1.63B1.13B551M1.7B(361.84M)
Stock-Based Compensation700M791M865M1.04B0
Change in Working Capital(73M)(796M)(369M)(706M)(3.08B)
Accounts Receivables(352M)(397M)(1.5B)(931M)(1.13B)
Inventory(102M)(560M)(546M)(225M)34.17M
Accounts Payables(111M)(181M)479M(105M)(274.4M)
Other Working Capital492M342M1.2B555M(1.71B)
Other Non-Cash Items(15.68B)359M(3.44B)(2.43B)3.27B
Operating Cash Flow15.07B14.24B14.46B17.62B19.24B
Capital Expenditures(2.56B)(2.24B)(2.75B)(3.81B)(1.56B)
Acquisitions (Net)20.46B(864M)(3.57B)(3.83B)(3.01B)
Purchases of Investments(16.59B)(34.81B)(747M)(3.65B)(304.55M)
Sales of Investments2.74B39.49B11.6B3.7B2.19B
Other Investing Activities(1.34B)(1.43B)(624M)(2.38B)140.72M
Investing Cash Flow4.21B1.47B5.6B(7.51B)(4.9B)
Debt Repayment(5.67B)(2.59B)(1.94B)4.39B2.72B
Common Stock Issued000027.14M
Common Stock Repurchased(3.06B)(10.65B)(8.72B)(8.33B)(9.26B)
Dividends Paid(7.37B)(7.51B)(7.26B)(7.62B)(7.86B)
Other Financing Activities(169M)181M3.63B(177M)(577.95M)
Financing Cash Flow(16.26B)(20.56B)(14.28B)(11.74B)(14.94B)
Effect of Forex Changes(266M)(32M)100M(298M)579.07M
Net Change in Cash2.75B(4.89B)5.88B(1.93B)(24M)
Free Cash Flow12.52B12B11.71B13.81B17.69B

Novartis AG

NYSE:NVS

Intrinsic Alpha fair value

Locked

Current Price

$155.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.